.webp)
Share
Dr. Adam Zong
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology, and other therapeutic areas, has appointed Dr. Adam Zong as President.
Dr. Zong will be based in Shanghai and will report directly to Dr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour BioMed.
In his new role, Dr. Zong will be responsible for strengthening the Company’s internal product pipeline, advancing the strategic development of its overall portfolio, and leading asset strategy and partnership initiatives. He will also play a key role in aligning cross-functional efforts to accelerate development timelines and enhance the value of Harbour BioMed’s pipeline.
Dr. Zong brings more than 20 years of global biopharmaceutical leadership experience, with deep expertise in portfolio strategy, commercial operations, and business development across multinational pharmaceutical companies and emerging biotechnology organizations.
Prior to joining Harbour BioMed, he served as Principal Consultant at Arc Nouvel Clinical Development Consulting. He was also the founding Chief Executive Officer of Hengrui Therapeutics U.S., where he led the company’s global expansion. Earlier in his career, Dr. Zong held senior leadership positions at Merck & Co., Bristol Myers Squibb, Schering-Plough, and Pfizer, where he managed global franchises, led large commercial portfolios, and oversaw major business development, licensing, and M&A transactions.
Dr. Zong holds a PhD in Oncology and Virology from The Rockefeller University and an MBA in Finance and Entrepreneurial Management from The Wharton School of the University of Pennsylvania.
